共 50 条
- [41] The role of quantitative tumor burden based on [68 Ga]Ga-DOTA-NOC PET/CT in well-differentiated neuroendocrine tumors: beyond prognosisEuropean Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 525 - 534Luohai ChenNuerailaguli JumaiQiao HeMan LiuYuan LinYanji LuoYu WangMin-hu ChenZhirong ZengXiangsong ZhangNing Zhang
- [42] Predictive and Prognostic Role of Pre-Therapy and Interim 68Ga-DOTATOC PET/CT Parameters in Metastatic Advanced Neuroendocrine Tumor Patients Treated with PRRTCANCERS, 2022, 14 (03)Durmo, RexhepFilice, AngelinaFioroni, FedericaCervati, VeronicaFinocchiaro, DomenicoCoruzzi, ChiaraBesutti, GiuliaFanello, SilviaFrasoldati, AndreaVersari, Annibale
- [43] Concordance between baseline 68Ga-DOTATOC PET/CT and first post-dose 177Lu-oxodotreotide SPECT/CT (177Lu-DOTATATE-SPECT/CT) images in patients with neuroendocrine tumors (NETs) treated with peptide receptor radionuclide therapy (PRRT)EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S466 - S467Cardozo Saavedra, A.Simo-Perdigo, M.Garcia-Burillo, A.Villasboas-Rosciolesi, D.Hernando, J.Capdevila, J.Menendez-Sanchez, S.Bellviure-Meiro, R.Dellepiane-Clarke, F.Aguade-Bruix, S.
- [44] Use of 68Ga-DOTA-TATE PET/CT for predicting the dose of 177Lu-DOTA-TATE therapy in patients with neuroendocrine tumors (NETs)JOURNAL OF NUCLEAR MEDICINE, 2012, 53Scheler, SimoneFischer, RichardFani, MelpomeniMaecke, HelmutWeber, WolfgangWild, Damian
- [45] Role of Combined 68Ga-DOTATOC and 18F-FDG PET-CT in the Diagnostic Workup of Well Differentiated Pancreas Neuroendocrine Tumors (PanNETs): A Surgical SeriesNEUROENDOCRINOLOGY, 2015, 102 (1-2) : 113 - 113Ortolani, S.Butturini, G.Malpaga, A.Cingarlini, S.Malfatti, VCapelli, P.Ruzzenente, A.Regi, P.Vallerio, P.Grego, E.Tortora, G.Scarpa, A.Bassi, C.Salgarello, M.
- [46] Head-to-Head Comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective StudyJOURNAL OF NUCLEAR MEDICINE, 2020, 61 (06) : 897 - 903Zhu, WenjiaCheng, YuejuanWang, XuezhuYao, ShaoboBai, ChunmeiZhao, HongJia, RuXu, JianmingHuo, Li
- [47] Inter- and intra-tumoral heterogeneity on [68Ga]Ga-DOTA-TATE/[68Ga]Ga-DOTA-TOC PET/CT predicts response to [177Lu]Lu-DOTA-TATE PRRT in neuroendocrine tumor patientsEJNMMI REPORTS, 2024, 8 (01)Gadens Zamboni, CamilaDundar, AycaJain, SanchayKruzer, MarcLoeffler, Bradley T.Graves, Stephen A.Pollard, Janet H.Mott, Sarah L.Dillon, Joseph S.Graham, Michael M.Menda, YusufShariftabrizi, Ahmad
- [48] Tumour-to-liver ratio determined by [68Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumoursEJNMMI RESEARCH, 2020, 10 (01)Kim, Yong-ilYoo, ChanghoonOh, Seung JunLee, Sang JuKang, JunhoHwang, Hee-SangHong, Seung-MoRyoo, Baek-YeolRyu, Jin-Sook
- [49] 68Ga-DOTATATE PET/CT for the Early Prediction of Response to Somatostatin Receptor-Mediated Radionuclide Therapy in Patients with Well-Differentiated Neuroendocrine TumorsJOURNAL OF NUCLEAR MEDICINE, 2010, 51 (09) : 1349 - 1360Haug, Alexander R.Auernhammer, Christoph J.Waengler, BjoernSchmidt, Gerwin P.Uebleis, ChristopherGoeke, BurkhardCumming, PaulBartenstein, PeterTiling, ReinholdHacker, Marcus
- [50] Tumour-to-liver ratio determined by [68Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumoursEJNMMI Research, 10Yong-il KimChanghoon YooSeung Jun OhSang Ju LeeJunho KangHee-Sang HwangSeung-Mo HongBaek-Yeol RyooJin-Sook Ryu